Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Exclusion Criteria

• •Primary refractory disease (progressive disease on initial platinum based chemotherapy) or chemotherapy-resistant disease (disease progression within 90 days of completion of initial chemotherapy)
• •Patients who are pregnant or lactating
• •Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =\< 2 weeks prior to cycle 1 day 1; any clinical trial therapy (including investigational anti-cancer study) =\< 3 weeks prior to cycle 1 day 1
• •Prior treatment with selinexor
• •Major surgery within 3 weeks before day 1
• •Unstable cardiovascular function:
• •* Electrocardiogram (ECG) abnormalities requiring treatment, or
• •* Congestive heart failure (CHF) of New York Heart Association (NYHA) class \>= 3
• •* Myocardial infarction (MI) within 3 months
• •* Symptomatic ischemia or angina
• •Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
• •Known to be human immunodeficiency virus (HIV) seropositive
• •Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or hepatitis B surface antigen (HBsAg) (hepatitis B virus \[HBV\] surface antigen)
• •Serious psychiatric or medical conditions that could interfere with treatment
• •History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1
• •Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
• •Patients with \> 3 liver metastases at time of enrollment
• •Patients with coagulation problems and active bleeding in the last month (peptic ulcer, epistaxis, spontaneous bleeding)
• •Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
• •Patients who are severely underweight (body mass index \[BMI\] less than 17) or patients with a body surface area (BSA) \< 1.4 m\^2 as calculated per Dubois 1916 or Mosteller 1987
• •Uncontrolled brain metastases or leptomeningeal involvement; patients with brain metastases are permitted if they have received appropriate therapy and demonstrated control of the brain metastases or leptomeningeal disease following therapy; patients with known brain metastases will require magnetic resonance imaging (MRI) brain to demonstrate disease control prior to enrollment (lack of symptom progression for two weeks off therapeutic doses of steroids, excluding chronic steroids used for control of chronic obstructive pulmonary disease \[COPD\])
• •Prior cancer diagnosis is allowed if patient is disease-free for \>= 3 years, or disease free for \< 3 years for treated basal cell/ squamous cell skin cancer or in situ cervical cancer